Article
Oncology
Sang Hee Lee, Ji Young Choi, Jae Ho Jung, In Ho Song, Hyun Soo Park, Nunzio Denora, Francesco Leonetti, Sang Eun Kim, Byung Chul Lee
Summary: The study demonstrated that integrin-targeted PRRT combined with TMZ significantly reduced tumor volume in glioblastoma, showing a superior effect compared to using each agent individually. The combination therapy proved to be an effective new medical tool for treating glioblastoma.
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Nadia Allahyarzadeh Khiabani, Mohammad Amin Doustvandi, Fateme Mohammadnejad, Elnaz Salmani Hassan Kohal, Neda Boushehri, Mahdi Jafarlou, Behzad Baradaran
Summary: This study aimed to investigate the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. The results demonstrated that the combined treatment of B7H6-siRNA and temozolomide had a synergistic effect on inhibiting the cancerous features of U87 cell line. Down-regulating B7H6-siRNA expression inhibited cell viability and increased sensitivity to temozolomide in glioblastoma cancer cells. Furthermore, the combined treatment showed reduced cell migration ability and stemness, and increased apoptosis compared to individual treatments. These findings suggest that the combination of B7H6-siRNA and temozolomide could be a promising strategy for glioblastoma cancer therapy.
EXPERIMENTAL CELL RESEARCH
(2023)
Article
Oncology
Yossi Nishri, Maayan Vatarescu, Ishai Luz, Lior Epstein, Mirta Dumancic, Sara Del Mare, Amit Shai, Michael Schmidt, Lisa Deutsch, Robert B. Den, Itzhak Kelson, Yona Keisari, Lior Arazi, Tomer Cooks, Vered Domankevich
Summary: The combination of diffusing alpha-emitters radiation therapy (DaRT) with standard-of-care chemotherapy or antiangiogenic therapy shows promise in improving the treatment of glioblastoma multiforme (GBM) patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Zhiwei Hou, Huaguo Wu, Ningning Luo, Shuo Li, Xiang Zhang, Shuai Dong, Dongyuan Zhu, Hui Zhang, Rongjie Tao
Summary: Glioblastoma (GBM) is a common primary brain tumor with poor prognosis. More than half of GBMs have epidermal growth factor receptor (EGFR) gene alterations. This study identified an EGFR p.L858R mutation in a patient with recurrent GBM for the first time. Treatment with Almonertinib, Anlotinib, and Temozolomide led to 12 months of progression-free survival. This suggests that EGFR may be a new marker for GBM treatment with Almonertinib.
Editorial Material
Biochemistry & Molecular Biology
Kirit Singh, Kelly M. Hotchkiss, Ian F. Parney, John De Groot, Solmaz Sahebjam, Nader Sanai, Michael Platten, Evanthia Galanis, Michael Lim, Patrick Y. Wen, Giuseppe Minniti, Howard Colman, Timothy F. Cloughesy, Minesh P. Mehta, Marjolein Geurts, Isabel Arrillaga-Romany, Annick Desjardins, Kirk Tanner, Susan Short, David Arons, Elizabeth Duke, Wolfgang Wick, Stephen J. Bagley, David M. Ashley, Priya Kumthekar, Roel Verhaak, Anthony J. Chalmers, Anoop P. Patel, Colin Watts, Peter E. Fecci, Tracy T. Batchelor, Michael Weller, Michael A. Vogelbaum, Matthias Preusser, Mitchel S. Berger, Mustafa Khasraw
Summary: A breakthrough in drug discovery for glioblastoma necessitates the consecutive collection of central nervous system tissue through window of opportunity trials.
Article
Oncology
Kenichiro Asano, Toshio Fumoto, Masashi Matsuzaka, Seiko Hasegawa, Naoya Suzuki, Kenichi Akasaka, Kosuke Katayama, Akihisa Kamataki, Akira Kurose, Hiroki Ohkuma
Summary: This investigator-initiated study aimed to investigate the effectiveness of induction combination chemoradiotherapy and long-term maintenance therapy for glioblastoma. The 2-year overall survival tended to exceed historical controls, but further research may be needed as the lower limit of the 95% confidence interval was below 31.7%.
Article
Cell Biology
Avijit Dey, S. M. Anisul Islam, Rekha Patel, Mildred Acevedo-Duncan
Summary: The combination therapy of ICA and TMZ successfully inhibited the viability of glioblastoma cells, promoted apoptosis, and reduced cell invasion by targeting the FAK/Paxillin pathway. In vivo experiments also demonstrated that the combination of ICA and TMZ reduced glioblastoma tumor growth and volume in mice.
CELLULAR SIGNALLING
(2021)
Article
Oncology
B. Kasenda, D. Koenig, M. Manni, R. Ritschard, U. Duthaler, E. Bartoszek, A. Baerenwaldt, S. Deuster, G. Hutter, D. Cordier, L. Mariani, J. Hench, S. Frank, S. Kraehenbuehl, A. Zippelius, C. Rochlitz, C. Mamot, A. Wicki, H. Laeubli
Summary: This study evaluated the tolerability and effectiveness of anti-EGFR immunoliposomes in treating patients with relapsed glioblastoma harboring an EGFR amplification. The results showed that these immunoliposomes were unable to cross the blood-brain barrier, but could deliver drugs to glioblastoma tissue. In terms of efficacy, the median progression-free survival was 1.5 months and the median overall survival was 8 months.
Review
Oncology
Kirit Singh, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, Howard Colman, David M. Ashley, Susan M. Chang, Rifaquat Rahman, Evanthia Galanis, Alireza Mansouri, Vinay K. Puduvalli, David A. Reardon, Solmaz Sahebjam, John H. Sampson, John Simes, Donald A. Berry, Gelareh Zadeh, Tim F. Cloughesy, Minesh P. Mehta, Steven Piantadosi, Michael Weller, Amy B. Heimberger, Mustafa Khasraw
Summary: Immunotherapy has not shown significant improvement in outcomes for glioblastoma patients due to the multiple and unique mechanisms of immune evasion and escape in this highly heterogeneous tumor. Combinatorial approaches of immune-oriented therapy are required to overcome these mechanisms. The design of clinical trials evaluating these approaches needs careful consideration.
CLINICAL CANCER RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Zahra Jodari Mohammadpour, Reza Mohammadzadeh, Darya Javadrashid, Amir Baghbanzadeh, Mohammad Amin Doustvandi, Nesa Barpour, Behzad Baradaran
Summary: This study aimed to evaluate the effect of SIX4-siRNA on A-172 glioblastoma cells, its role as a tumor suppressor, and its combination with TMZ. The results showed that silencing SIX4-siRNA expression reduced the cell viability of A-172 cells and sensitized these cells to TMZ. Furthermore, an increase in apoptosis and cell cycle arrest, and a decrease in migration were observed. The combination of SIX4-siRNA and TMZ can be a very useful strategy for successful glioblastoma treatment.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Ling-Xiao Zhao, Zhi-Qiang Gong, Qi Zhang, Da-Long He, Ri-Le Ge, Jin Meng, Hang Ren, Yong-Gang Fan, Zhan-You Wang
Summary: Glioblastoma, a highly malignant tumor, can be treated by inducing ferroptosis using graphdiyne-based nanoplatforms. These nanoplatforms can penetrate the blood-brain barrier and release the therapeutic drug in the tumor tissue, leading to inhibition of tumor growth and prolonged survival.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Biochemistry & Molecular Biology
M. Janaki Ramaiah, K. Rohil Kumar
Summary: Glioblastoma multiforme (GBM) is an aggressive brain cancer with a short survival period, where mTOR and EGFR mediated signaling pathways play a crucial role in tumor aggressiveness and chemoresistance. Recent studies show that microRNAs can regulate these pathways, affecting cell sensitivity to chemotherapy.
MOLECULAR BIOLOGY REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Ruth M. Urbantat, Claudius Jelgersma, Susan Brandenburg, Melina Nieminen-Kelha, Irina Kremenetskaia, Julia Zollfrank, Susanne Mueller, Kerstin Rubarth, Arend Koch, Peter Vajkoczy, Gueliz Acker
Summary: Tumor recurrence in GBM is a major challenge, with upregulation of IL8/CXCL2/CXCR2 signaling induced by TMZ. High TAM infiltration predicts poor survival, while more patients express IL8 in recurrent tumors and TMZ therapy maintains CXCL2 expression. Combination therapy shows enhanced anti-tumoral effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Rajappa S. Kenchappa, Athanassios Dovas, Michael G. Argenziano, Christian T. Meyer, Lauren E. Stopfer, Matei A. Banu, Brianna Pereira, Jessica Griffith, Afroz Mohammad, Surabhi Talele, Ashley Haddock, Natanael Zarco, William Elmquist, Forest White, Peter Sims, Vito Quaranta, Peter Sims, Peter Canoll, Steven S. Rosenfeld
Summary: This study reveals a mechanism of resistance to Kif11 inhibitors in glioblastoma, where suppression of apoptosis driven by activation of STAT3 plays a crucial role. Simultaneous inhibition of SRC and EGFR can reverse this resistance and significantly prolong survival in mice. These findings provide a translational actionable approach to overcome Kif11 inhibitor resistance.
Article
Cell Biology
Joel D. Leverson, Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert, Dolores Diaz, Stephen K. Tahir, Lisa D. Belmont, Paul Nimmer, Yu Xiao, Xiaoju Max Ma, Kym N. Lowes, Peter Kovar, Jun Chen, Sha Jin, Morey Smith, John Xue, Haichao Zhang, Anatol Oleksijew, Terrance J. Magoc, Kedar S. Vaidya, Daniel H. Albert, Jacqueline M. Tarrant, Nghi La, Le Wang, Zhi-Fu Tao, Michael D. Wendt, Deepak Sampath, Saul H. Rosenberg, Chris Tse, David C. S. Huang, Wayne J. Fairbrother, Steven W. Elmore, Andrew J. Souers
SCIENCE TRANSLATIONAL MEDICINE
(2015)
Article
Oncology
Jieyi Wang, Liliane Goetsch, Lora Tucker, Qian Zhang, Alexandra Gonzalez, Kedar S. Vaidya, Anatol Oleksijew, Erwin Boghaert, Minghao Song, Irina Sokolova, Ekaterina Pestova, Mark Anderson, William N. Pappano, Peter Ansell, Anahita Bhathena, Louie Naumovski, Nathalie Corvaia, Edward B. Reilly
Article
Oncology
Jieyi Wang, Mark G. Anderson, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Lora Tucker, Qian Zhang, Edward K. Han, Joann P. Palma, Louie Naumovski, Edward B. Reilly
CLINICAL CANCER RESEARCH
(2017)
Article
Oncology
Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya, Michael J. Mitten, Suzanne Norvell, Hugh D. Falls, Peter J. DeVries, Dong Cheng, Jonathan A. Meulbroek, Fritz G. Buchanan, Laura M. McKay, Neal C. Goodwin, Edward B. Reilly
MOLECULAR CANCER THERAPEUTICS
(2016)
Article
Pharmacology & Pharmacy
Kedar S. Vaidya, Anatol Oleksijew, Lora A. Tucker, William N. Pappano, Mark G. Anderson, Christine M. Grinnell, Qian Zhang, Sarah J. Heighton, Michael J. Mitten, Sasmita Mishra, Joann P. Palma, Jieyi Wang, Edward B. Reilly, Erwin R. Boghaert
Article
Oncology
Erwin R. Boghaert, Xin Lu, Paul E. Hessler, Thomas P. McGonigal, Anatol Oleksijew, Michael J. Mitten, Kelly Foster-Duke, Jonathan A. Hickson, Vitor E. Santo, Catarina Brito, Tamar Uziel, Kedar S. Vaidya
Article
Oncology
Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya, Hugh D. Falls, Michael J. Mitten, Peter J. DeVries, Lorenzo Benatuil, Chung-Ming Hsieh, Jonathan A. Meulbroek, Sanjay C. Panchal, Fritz G. Buchanan, Kenneth R. Durbin, Martin J. Voorbach, David R. Reuter, Sarah R. Mudd, Lise I. Loberg, Sherry L. Ralston, Diana Cao, Hui K. Gan, Andrew M. Scott, Edward B. Reilly
MOLECULAR CANCER THERAPEUTICS
(2018)
Article
Oncology
Douglas R. Hurst, Mick D. Edmonds, Gary K. Scott, Christopher C. Benz, Kedar S. Vaidya, Danny R. Welch
Article
Oncology
Thomas M. Bodenstine, Kedar S. Vaidya, Aimen Ismail, Benjamin H. Beck, Leah M. Cook, Anne R. Diers, Aimee Landar, Danny R. Welch
Article
Oncology
Wen Liu, Benjamin H. Beck, Kedar S. Vaidya, Kevin T. Nash, Kyle P. Feeley, Scott W. Ballinger, Keke M. Pounds, Warren L. Denning, Anne R. Diers, Aimee Landar, Animesh Dhar, Tomoo Iwakuma, Danny R. Welch
Article
Oncology
Yeon-Jin Kwon, Douglas R. Hurst, Adam D. Steg, Kun Yuan, Kedar S. Vaidya, Danny R. Welch, Andra R. Frost
CLINICAL & EXPERIMENTAL METASTASIS
(2011)
Article
Biochemistry & Molecular Biology
Thomas M. Bodenstine, Kedar S. Vaidya, Aimen Ismail, Benjamin H. Beck, Anne R. Diers, Mick D. Edmonds, Gina T. Kirsammer, Aimee Landar, Danny R. Welch
Article
Oncology
Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Wenqing Gao, Joann P. Palma, Diana Cao, Puey-Ling Chia, Thomas John, Hui K. Gan, Andrew M. Scott, Edward B. Reilly
MOLECULAR CANCER THERAPEUTICS
(2020)
Review
Oncology
Erwin R. Boghaert, Megan C. Cox, Kedar S. Vaidya
Summary: ADCs are an important tool in clinical disease management in oncology, but their widespread development and application are hindered by a narrow therapeutic index. This review focuses on the interplay between structural characteristics of ADCs, pathophysiology of cancerous tissues, and their reciprocal consequences on ADC properties and functions. It argues for the expansion of payload mechanisms and the consideration of disease-specific vulnerabilities to increase the probability of clinical success.